ROIV's Quality Score rose 1 point on Tue, Nov 10, to 13. Sales grew 102% on the year, from 102%.
Follow ROIV's news. Pro members can get an alert when Roivant Sciences files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 15% from Nov 2 to Nov 10.
| The chart | Stronger than 92% of stocks |
| Latest filing | 8-K, Nov 9 |
Roivant Sciences' Brepocitinib Delivers Positive Phase III Uveitis Results
ROIV closed +5.4% that day on 2.2x normal volume.
Mon Nov 16: Jefferies 17th Annual London Global…Investor conference · date confirmed.
1 more date ahead: the investor day, for Pro members.
After its last 4 reports it closed +10.8% on average, higher 4 of 4 times.
CEO Eric Venker sold 200,000 shares on Nov 3, under a planned sale. 30 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Above Averagefor quality, not price, 7 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. ROIV scores 13 today, against a median of 8 over its last 20 recorded sessions.
ROIV is #14 of 90 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 14 |
Expected to report Thu Feb 4, before the open (in 86 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $35.1M.
“This decrease was primarily driven by decreases in personnel-related expense of $7.4 million, program-specific costs of $6.4 million and share-based compensation of $3.0 million.”
ROIV's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“This increase was primarily due to higher selling, general and administrative expenses as a result of the commercial launch of LISRAYA.”
From its results filing (SEC filing · Nov 9)
Its share count fell 0.9% a year over 3 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 9, 2026 | +1.5% | +4.6% | not yet |
| Aug 6, 2026 | -4.3% | +1.5% | +4.5% |
| May 20, 2026 | +4.9% | +14.9% | +4.9% |
Sales grew in two of the last five years, to $8.3M in 2025. It made a profit in one of the six years.
RSI 66.3, MACD above signal, above both averages. Not scored.
3 insiders sold $176M across 20 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ROIV is under 0.1% of SCHG and under 0.1% of VTI, the most of the 24 funds Breakaway covers, by each fund's latest filing, Jun 30 to Aug 31, 2026.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
“The development and commercialization of new drug products is highly competitive.”
ROIV scores 13 today, which Breakaway calls Above Average. It is #14 of 90 in Pharma by Quality Score, with 7 of 14 chart checks firing. Up 15% from Nov 2 to Nov 10. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ROIV scores 13 today, which Breakaway calls Above Average (11 to 14). That is #14 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ROIV's 13.
3 insiders sold $176M across 20 filings in the last 6 months. No open-market buys on record. The newest is Mayukh Sukhatme, President & CIO, who sold $6.4M on Aug 19. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.